An Experimental Implant Uses Electricity to Convert Excess Blood Sugar
Key takeaways
-
Researchers developed an electrically powered implant that converts glucose into gluconate, a substance the body can eliminate through urine.
-
In a six-week mouse study, the system regulated blood sugar and led to weight loss.
-
A glucose sensor and wireless controller activate the implant when glucose rises and switch it off when levels return to the desired range.
-
The device has not been tested in humans. Its long-term safety, durability, and effectiveness remain open questions.
A different way to handle excess glucose
An experimental implant developed by researchers at ETH Zurich takes a different approach to blood sugar control: rather than delivering insulin or another medication, it uses electricity to chemically convert glucose.
The team, led by Martin Fussenegger, designed the device to turn glucose into gluconate. The body can then eliminate that substance through urine, removing some glucose that would otherwise remain available for energy use or storage. The findings were published in Science.
The distinction is conversion. Rather than signaling the body to handle glucose differently, the device directly changes some of that glucose into another substance.
How the implant works
At its center is graphite felt covered with tiny gold structures and smaller platinum particles. Together, these materials form an electrically activated catalyst—a surface that enables the glucose-conversion reaction without relying on living cells or enzymes. The implant receives power wirelessly.
The control system connects that catalyst to a glucose sensor and a digital controller:
-
A sensor measures glucose concentrations in tissue.
-
It sends readings to a smartphone or smartwatch.
-
When glucose rises above the target range, the system activates the implant.
-
Once glucose returns to the desired range, the implant switches off.
This feedback arrangement, called closed-loop control, is intended to limit operation to periods when glucose is elevated and reduce the risk of driving it too low. That design goal still needs clinical testing.
What the experiments showed
The researchers first tested the catalyst in five liters of glucose-containing nutrient solution—approximately the volume of blood in an adult human. This demonstrated glucose conversion at that scale, but it was not a test in human blood or a person.
They then evaluated the implant in mice with elevated blood sugar. Over six weeks, it regulated blood sugar, the animals lost weight, and the implant continued functioning reliably. The researchers reported good tolerance and no evidence of tissue damage caused by electrical or thermal effects during those experiments.
The weight finding fits the device’s proposed mechanism: converting glucose into an excretable substance could reduce the amount available for storage. However, the ScienceDaily report does not provide numerical results for weight loss or glucose changes, limiting how precisely readers can assess the size of those effects.
Why the approach is interesting—and still preliminary
Earlier systems from the research group relied on engineered biological components. This design instead uses inorganic materials, potentially avoiding some challenges associated with keeping cells or enzymes functional inside a device.
Whether that translates into a durable, practical system remains to be established.
The biggest gap is human evidence. Six weeks of successful operation in mice cannot establish long-term safety or show how well the implant would control glucose in people. The team’s next objective is to develop the experimental system into a medical device suitable for further development and eventual clinical testing.
The takeaway
The study demonstrates an unusual possibility: using a wirelessly powered catalyst to convert excess glucose into a substance the body can eliminate, with a sensor deciding when the device should work.
For now, it remains an experimental technology—not an available tool for blood sugar control or weight management. Its promise depends on whether future studies can reproduce the findings safely and reliably in humans.
References:
- Debasis Maity, Preetam Guha Ray, Peter Buchmann, Ghislaine Charpin-El Hamri, Martin Fussenegger. Wireless electrocatalytic closed-loop system for drug-free management of dia-besity. Science, 2026; 394 (6822) DOI: 10.1126/science.ady8560